Everolimus-induced somatostatin receptor overexpression in a rectal neuroendocrine tumor patient may promote somatostatin receptor-guided radionuclide therapy (peptide receptor radiotherapy) as an additional treatment option

We present a case of Grade II, well-differentiated rectal neuroendocrine tumor in a 39-year-old patient. Following different sequential treatment modalities, the disease progressed both on metabolic (18F-fluorodeoxyglucose positron emission tomography-computed tomography [(18)F-FDG PET/CT]) and soma...

Descripción completa

Detalles Bibliográficos
Autores principales: Mileva, Magdalena, Wimana, Zéna, Flamen, Patrick, Karfis, Ioannis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Medknow Publications & Media Pvt Ltd 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488891/
https://www.ncbi.nlm.nih.gov/pubmed/34703403
http://dx.doi.org/10.4103/wjnm.WJNM_120_20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8488891/
https://www.ncbi.nlm.nih.gov/pubmed/34703403
http://dx.doi.org/10.4103/wjnm.WJNM_120_20

Ejemplares similares